Pills on top of coin stacks, piggy (Photo: Shutterstock)

It’s commonly known that the cost of prescription drugs in the U.S. has been rising well above inflation, 7.5% in some cases. Ironically the current pandemic-driven inflation rate may technically put an end to that, though sadly it will not stop rising drug prices.

According to the IQVIA Institute, specialty drugs account for 53% and branded drugs account for 30% of the overall drug spend, most of which are still under patent with limited competition. However, generics and biosimilar drugs are available at a substantially lower price for some of these drugs, but surprisingly evidence shows that these lower cost options are often excluded from our formularies by the very vendor we entrust to manage our costs.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

 

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2022 ALM Global, LLC. All Rights Reserved.